UK researchers conducted a retrospective case-series study of four children diagnosed with solid cancers at age 16 or younger, aiming to assess the time to and survival following a second cancer diagnosis. In those who received radiotherapy for the initial cancer, the median time to a second primary cancer diagnosis was 13.3 years, with a
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different phenotypes of the Li-Fraumeni Syndrome. Emilie Montellier, PhD (1), Nathanaël Lemonnier, PhD (1), Judith Penkert, MD (2), Claire Freycon, MD (1,3,4), Sandrine Blanchet, MSc (1), Amina Amadou, PhD (1,5), Florent Chuffart, PhD (1), Nicholas Fischer,
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome (LFS) to review the current understanding of the condition and propose consensus guidelines for surveillance. This summary provides an overview of the clinical and genetic aspects of this aggressive cancer predisposition syndrome. The expert panel concluded that
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS), and your thoughts about an upcoming clinical trial for people with LFS.Liquid biopsy is a promising new cancer screening technique that can detect signs of cancer in a blood sample, and researchers are planning a study adding
Northwestern University is conducting a groundbreaking study focused on understanding patient perspectives on dating and disclosure to romantic partners for males diagnosed with Li-Fraumeni syndrome (LFS). Who are they looking for? Men aged 18–40 with a diagnosis of LFS All perspectives are welcome, including those who are single, dating, married, straight, or
Breast, ovarian, pancreative, and prostate cancer have been added to the National Comprehensive Cancer Network Genetic/Familial High-Risk Assessment Guidelines following a recent expansion that includes colorectal, endometrial, and gastric cancers. This expansion of tumor types reflects the latest advancements in genetic research and offers life-saving insights for those with cancer and those with a
CancerNetwork, an arm of the prestigious journal Oncology, joined LFSA at the 7th International LFS Association Symposium to report on the latest advances in LFS research and clinical therapies. Reflected here are highlights of presentations by global experts. Co-chair of the symposiumm, Suzanne P. MacFarland, MD, shared a thought-provoking presentation on liquid biopsy and
CancerNetwork, an arm of the prestigious journal Oncology, joined LFSA at the 7th International LFS Association Symposium to report on the latest advances in LFS research and clinical therapies. Reflected here are highlights of presentations by global experts.. Among them, Payal Khincha, MBBS, MSHS, shared a presentation on the progress of using metformin to
Presentations on advancements in early detection brought compelling research to light at the 7th International LFS Association Symposium. Trevor Pugh, PhD, FACMG, shared some early highlights from a randomized trial intended to assess the ability of cell-free DNA (cfDNA) sequencing to detect cancers in patients with LFS and similar cancer predisposition syndromes. Pugh is
The 7th International LFS Association Symposium delivered a powerful global collaboration intended to provide the best of care and hope to all of those with LFS and their families. In his talk on advancements in care, Michael J. Hall, MD, MS, FASCO, acknowledged how isolating it may be individuals receiving a diagnosis for LFS
P.O. Box 6458
Holliston, MA 01746, USA
Phone: 1-833-4MYLFSA (1-833-469-5372)
Email: info@lfsassociation.org
© Copyright 2025 | Li-Fraumeni Syndrome Association | All Rights Reserved | Terms & Conditions | Privacy Policy
